Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 15/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MERTK | Q12866 | 3/20 | 0.41 |
| ▸ | FLT3 | P36888 | 2/20 | 0.41 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.41 |
| ▸ | GAS6 | Q14393 | 2/20 | 0.41 |
| ▸ | AXL | P30530 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4764945 | 0.94 | TTK (0.48) | TTKADORA3ADORA1MERTKFLT3 | |
| SCHEMBL4766824 | 0.94 | TTK (0.48) | TTKADORA3ADORA1MERTKAXL | |
| SCHEMBL4766540 | 0.93 | TTK (0.57) | TTKADORA3 | |
| SCHEMBL4975608 | 0.92 | TTK (0.46) | TTKADORA3ADORA1MERTKFLT3 | |
| SCHEMBL4972483 | 0.92 | TTK (0.46) | TTKADORA3ADORA1MERTKAXL | |
| SCHEMBL4976863 | 0.90 | TTK (0.47) | TTKADORA3ADORA1MERTKAXL | |
| SCHEMBL4766884 | 0.90 | TTK (0.47) | TTKADORA3ADORA1MERTKAXL | |
| SCHEMBL4979267 | 0.88 | TTK (0.51) | TTKMERTKTYRO3AXL | |
| SCHEMBL4975672 | 0.87 | TTK (0.49) | TTKADORA3ADORA1MERTKAXL | |
| SCHEMBL4979254 | 0.85 | TTK (0.58) | TTKMERTKFLT3TYRO3GAS6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| WO-2010111406-A2 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | VHL, TP53, ASAH2 | TTK 4589/4885ADORA3 1744/4885ADORA1 2771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.